Indian Association Calls for Biotechnology Fund
The Associated Chambers of Commerce and Industry of India (Assocham, www.assocham.org) have called for the establishment of a National Biotechnology Development Fund and a National Nanotechnology Development Fund, with outlays of approximately US $1 billion (Rs. 4,800 crore) and US $2 billion (Rs. 9,600 crore) respectively.
The Associated Chambers of Commerce and Industry of India (Assocham, www.assocham.org) have called for the establishment of a National Biotechnology Development Fund and a National Nanotechnology Development Fund, with outlays of approximately US $1 billion (Rs. 4,800 crore) and US $2 billion (Rs. 9,600 crore) respectively.
The funds, controlled by an autonomous management structure, would develop infrastructure-intensive industries in both the nanotech and biotech areas. Assocham contends that the establishment of national biotechnology and nanotechnology funds will inspire further development and motivate industry leaders to create adequate space within the Indian economy to allow for further expansion in these areas.
In the group’s recommendations submitted to the Indian government, the association also asked that a non-lapsable knowledge-acquisition fund be created to encourage students to return to studying the sciences. The association also contends that the government should create National Institutions of Nanotechnolgy–Biotechnology (IINBTs), with a structure similar to that of India’s Institutes of Information Technology.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
FDA Reopens Comment Period on HCP Immunogenicity Risk of Follow-on Recombinant Peptides
January 2nd 2025FDA is reopening the comment period for the Federal Register Notice, “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments”, until March 3, 2025.
